INT41 Gene Therapy for Neurodegenerative Diseases Granted Priority Patent Status – SMA News Today
|
INT41 Gene Therapy for Neurodegenerative Diseases Granted Priority Patent Status
SMA News Today INT41 gene therapy was specifically designed to target neurologic diseases caused by polyQ expansions, resulting in mutant proteins that accumulate in motor neurons and subsequently lead to cellular degeneration. The gene therapy aims to detect and … |
